AXSM - Axsome Therapeutics Inc. (AXSM) Q1 2024 Earnings Call Transcript
2024-05-06 11:55:24 ET
Axsome Therapeutics, Inc. (AXSM)
Q1 2024 Earnings Conference Call
May 06, 2024, 08:00 AM ET
Company Participants
Darren Opland - Director, Corporate Communications
Herriot Tabuteau - Chief Executive Officer
Nick Pizzie - Chief Financial Officer
Ari Maizel - Executive Vice President & Head, Commercial
Mark Jacobson - Chief Operating Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Leonid Timashev - RBC Capital Markets
Ash Verma - UBS
Ram Selvaraju - H.C. Wainwright
Marc Goodman - Leerink Partners
David Amsellem - Piper Sandler
Yatin Suneja - Guggenheim Partners
Jason Gerberry - Bank of America
Joon Lee - Truist Securities
Joel Beatty - Baird
David Hoang - Citi
Vikram Purohit - Morgan Stanley
Matt Kaplan - Ladenburg Thalmann
Myles Minter - William Blair
Troy Langford - TD Cowen
Presentation
Operator
Good morning, and welcome to the Axsome Therapeutics Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Darren Opland, Director of Corporate Communications at Axsome Therapeutics. Please go ahead.
Darren Opland
Good morning, and thank you all for joining us on today's conference call.
This morning, we issued our earnings press release providing a corporate update and details of the company's financial results for the first quarter of 2024. The release crossed the wire a short time ago, and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, amongst other things, the efficacy, safety, and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plans, future research and development plans, our commercial plans regarding Sunosi, Auvelity, and our other pipeline products; revenue projections and possible intended use of cash and investments.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today's date, and the company disclaims any obligation to update such statements.
Joining me on the call today are Dr. Herriot Tabuteau, Chief Executive Officer; Nick Pizzie, Chief Financial Officer; Mark Jacobson, Chief Operating Officer and Ari Maizel, Executive Vice President and Head of Commercial. Herriot will provide an overview of the company and progress made in the first quarter of 2024 as well as key upcoming milestones. Following Herriot, Nick will review our financial results, then Ari will provide a commercial update. We will then open the line for questions. The questions will be taken in the order they are received.
And with that, I will turn the call over to Herriot.
Herriot Tabuteau
Thank you, Darren. Good morning, everyone, and thank you for joining Axsome Therapeutics' first quarter 2024 financial results and business update conference call....
Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript